Accessibility helpSkip to navigationSkip to contentSkip to footer

Cookies on FT Sites

We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.

Accept cookies
Manage cookies
  • Sign In
  • Subscribe
Open side navigation menuOpen search bar
Financial Times
SubscribeSign InmyFT
  • Home
  • World
    Sections
    • World Home
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
    Most Read
    • Putin plans to deploy tactical nuclear weapons in Belarus
    • Rules for winding up big banks do not work, Swiss finance minister warns
    • IMF’s Georgieva warns of increased risks to financial stability
    • Tim Cook praises Apple’s ‘symbiotic’ relationship with China
    • No more ‘dangerous’ money printing to fund war, vows Ukraine central bank chief
  • US
    Sections
    • US Home
    • US Economy
    • US Companies
    • US Politics & Policy
    Most Read
    • Companies
      Sections
      • Companies Home
      • Banks in turmoil
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
      Most Read
      • Northvolt in talks to secure $5bn to become Europe’s biggest battery maker
      • Credit Suisse: the rise and fall of the bank that built modern Switzerland
      • Majority of Swiss want new UBS-Credit Suisse mega bank split up
      • First Republic hit by succession crisis before Fed began raising rates
      • Food producers take up record volumes of UK warehouse space
    • Tech
    • Markets
      Sections
      • Markets Home
      • Alphaville
      • Markets Data
      • Cryptofinance
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
      Most Read
      • Rules for winding up big banks do not work, Swiss finance minister warns
      • SEC raised concerns over hedge fund Rokos after losing bond bets
      • Traders pile into bets on gold price rally
      • Investing in early childhood is a down payment on all our futures
      • Japanese banks take post-SVB hit over bond fears
    • Climate
    • Opinion
      Sections
      • Opinion Home
      • Columnists
      • The FT View
      • Lex
      • Obituaries
      • Letters
      Most Read
      • Why five days in the office doesn’t add up
      • Investing in early childhood is a down payment on all our futures
      • Rupert Murdoch, last of the old romantics
      • How millennial faces fell out of fashion
      • Japan remains free from the tyranny of tipping
    • Work & Careers
      Sections
      • Work & Careers Home
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
      Most Read
      • Culture clash: the challenge of uniting fierce rivals UBS and Credit Suisse
    • Life & Arts
      Sections
      • Life & Arts Home
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
      Most Read
      • Everything I, an Italian, thought I knew about Italian food is wrong
      • Is France on the road to a Sixth Republic?
      • Courteney Cox: the Scream queen comes clean
      • Journalist Bari Weiss: ‘I hate bullies, period’
      • My liquid investigation into Italy’s love affair with Tennent’s Extra
    • HTSI
    MenuSearch
    • Home
    • World
    • US
    • Companies
    • Tech
    • Markets
    • Climate
    • Opinion
    • Work & Careers
    • Life & Arts
    • HTSI
    Financial Times
    SubscribeSign In

    Regeneron Pharmaceuticals Inc

    Add to myFT Digest

    Add this topic to your myFT Digest for news straight to your inbox

    • Wednesday, 28 December, 2022
      News in-depthDrugs research
      Race is on to develop new generation of weight-loss drugs

      Eli Lilly, Amgen, Pfizer and Regeneron follow Novo Nordisk into obesity treatments worth billions

    • Tuesday, 25 January, 2022
      Coronavirus treatment
      US drugs watchdog pulls authorisation for Covid monoclonal antibodies

      FDA says treatments from Regeneron and Eli Lilly ‘highly unlikely’ to work against Omicron strain

    • Tuesday, 30 November, 2021
      Coronavirus treatment
      Early tests show Regeneron drug may be less effective against Omicron

      Biotech says some antibody therapies may need to be modified to tackle new coronavirus variant

    • Friday, 22 October, 2021
      The Top LineTom Braithwaite
      Polarisation clouds the role for Regeneron’s Covid treatment

      Excessive boosterism and US partisan divisions risk undermining a limited but effective therapy

    • Tuesday, 19 October, 2021
      Coronavirus pandemic
      Regeneron claims Covid antibody drugs might have saved Colin Powell

      Suggestion ex-secretary of state would have benefited from treatment dismissed as ‘highly speculative’

    • Saturday, 2 October, 2021
      News in-depthCoronavirus pandemic
      ‘Too close for comfort’: demand for antibodies surges among unjabbed

      Supplies of Covid-19 drugs are running short, especially in states with low vaccination rates

    • Sunday, 27 June, 2021
      Pharmaceuticals sector
      Crispr gene-editing ‘revolution’ treats internal organ for first time

      US start-up co-founded by Nobel laureate marks breakthrough over therapies restricted to external cells

    • Wednesday, 16 June, 2021
      Coronavirus treatment
      Regeneron antiviral treatment saves lives of Covid patients in hospital

      Clinical trial shows the therapy helps those who fail to make their own antibodies against coronavirus

    • Monday, 12 April, 2021
      Regeneron’s Covid drug reduces risk of symptomatic illness, study finds

      Company to ask FDA to expand use of antibody cocktail as preventive treatment

    • Sunday, 22 November, 2020
      Coronavirus treatment
      Covid treatment given to Trump is cleared for use in US

      The FDA issues emergency use authorisation for Regeneron’s antibody treatment

    • Thursday, 5 November, 2020
      Coronavirus treatment
      Regeneron looks to target most in-need patients for Covid drug

      Company says it still needs to ‘button down’ plans to reach those who could benefit most from antibody treatment

    • Friday, 30 October, 2020
      US & Canadian companies
      Regeneron halts antibody trial in seriously ill Covid patients

      Drug hailed as coronavirus ‘cure’ by Donald Trump will still be studied in mild-to-moderate cases

    • Friday, 9 October, 2020
      LexCoronavirus treatment
      Regeneron/Eli Lilly/Covid-19: cocktail power Premium content

      Early signs are promising but there will be limits on how much the drug companies can charge

    • Friday, 9 October, 2020
      News in-depth
      Regeneron: the company that Trump claims cured his Covid

      President’s championing of novel therapy thrusts biotech group into uncomfortable spotlight

    • Thursday, 8 October, 2020
      Coronavirus treatment
      Covid drug used to treat Trump was tested using foetus cells

      Administration has tried to restrict practice of using aborted human tissue for scientific studies

    • Thursday, 8 October, 2020
      Coronavirus treatment
      Trump calls coronavirus treatment he received a ‘cure’

      Shares in manufacturers rise after US president praises experimental therapy

    • Saturday, 3 October, 2020
      Donald Trump
      Trump is moved to military hospital in Maryland

      President given experimental treatments for Covid-19 at Walter Reed facility

    • Wednesday, 27 May, 2020
      Pharmaceuticals sector
      Sanofi sells half of its Regeneron stake for $6.1bn

      Stock sale by French drugmaker will be used to develop new drugs and to fuel acquisitions

    • Tuesday, 26 May, 2020
      LexSanofi SA
      Sanofi/Regeneron: lockdown dispels a lock-up Premium content

      Extra firepower will expand French pharmaceutical company’s options

    • Monday, 25 May, 2020
      Drugs research
      Sanofi to slash $12bn stake in US biotech Regeneron

      Chief executive Paul Hudson says proceeds will go to scientific research and potentially acquisitions

    • Monday, 16 March, 2020
      Coronavirus pandemic
      Sanofi and Regeneron trial arthritis drug as coronavirus treatment

      Groups join effort to repurpose existing remedies in fight against global pandemic

    • Thursday, 27 February, 2020
      US equities
      Few winners emerge after brutal stock sell-off

      Netflix, Clorox and drugmakers weather market rout sparked by coronavirus

    • Monday, 11 February, 2019
      Drug prices
      Sanofi and Regeneron cut price of Praluent by 60%

      Drugmakers lower cost of anti-cholesterol drug amid slow take-up and political pressure

    • Tuesday, 1 May, 2018
      Companies By Region
      Sanofi slashes price of wannabe-blockbuster cholesterol drug

      Sales of Praluent have been hurt by the campaign to limit US pharmaceuticals costs

    • Thursday, 5 October, 2017
      Pharmaceuticals sector
      Regeneron wins legal case over heart drugs
    Previous page You are on page 1 Next page

    Useful links

    Support

    View Site TipsHelp CentreContact UsAbout UsAccessibilitymyFT TourCareers

    Legal & Privacy

    Terms & ConditionsPrivacy PolicyCookiesCopyrightSlavery Statement & Policies

    Services

    Share News Tips SecurelyIndividual SubscriptionsGroup SubscriptionsRepublishingExecutive Job SearchAdvertise with the FTFollow the FT on TwitterFT ChannelsSecondary Schools

    Tools

    PortfolioToday's Newspaper (ePaper)Alerts HubBusiness School RankingsEnterprise ToolsNews feedNewslettersCurrency Converter

    Community & Events

    FT CommunityFT Live EventsFT ForumsFT Board DirectorBoard Director Programme

    More from the FT Group

    Markets data delayed by at least 15 minutes. © THE FINANCIAL TIMES LTD 2023. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd.
    The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
    Financial Times

    International Edition

    Subscribe for full access
    • Switch to UK Edition

    Top sections

    • Home
    • World
      • Global Economy
      • UK
      • US
      • China
      • Africa
      • Asia Pacific
      • Emerging Markets
      • Europe
      • War in Ukraine
      • Americas
      • Middle East & North Africa
      • Australia & NZ
    • US
      • US Economy
      • US Companies
      • US Politics & Policy
    • Companies
      • Banks in turmoil
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
    • Tech
    • Markets
      • Alphaville
      • Markets Data
      • Cryptofinance
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
    • Climate
    • Opinion
      • Columnists
      • The FT View
      • Lex
      • Obituaries
      • Letters
    • Work & Careers
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
    • Life & Arts
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
    • Personal Finance
      • Property & Mortgages
      • Investments
      • Pensions
      • Tax
      • Banking & Savings
      • Advice & Comment
      • Next Act
    • HTSI
    • Special Reports

    FT recommends

    • Lex
    • Alphaville
    • Lunch with the FT
    • FT Globetrotter
    • #techAsia
    • Moral Money
    • FTfm
    • Newsletters
    • Video
    • Podcasts
    • News feed
    • FT Live Events
    • FT Forums
    • Board Director Programme
    • myFT
    • Portfolio
    • Today's Newspaper (ePaper)
    • Crossword
    • Our Apps
    • Help Centre
    • Subscribe
    • Sign In